Sign in
Taking people in South KoreaNo phase

Safety and effectiveness of secukinumab in skin and joint conditions in Korea

Observes secukinumab use in people with hidradenitis suppurativa, childhood psoriasis, or juvenile arthritis.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Status
Recruiting
People taking part
76 people, planned
Started
22 Dec 2025
Expected to end
15 Jun 2027
Type of study
Observational, 3 groups
Treatments tested
  • Secukinumab
Record updated
5 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe hidradenitis suppurativa, and children and teens aged 6 to 18 with moderate to severe plaque psoriasis or certain types of juvenile idiopathic arthritis. All are receiving or will receive Cosentyx.

Age
6 to 100 years. Hidradenitis suppurativa: 18 years and older. Plaque psoriasis and juvenile idiopathic arthritis: 6 to 18 years.
Sex
All sexes can join.
Disease stage
Moderate to severe hidradenitis suppurativa (adults) or moderate to severe plaque psoriasis (ages 6 to 18). For juvenile idiopathic arthritis: enthesitis related arthritis or juvenile psoriatic arthritis (ages 6 to 18).
Earlier treatment
People must be receiving Cosentyx or be about to receive it, within its approved use.

Main reasons for not taking part

  • People for whom Cosentyx is contraindicated under the national prescribing information
  • People taking part in other interventional clinical trials

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Hidradenitis suppurativa:
  • Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication
  • Patients who have agreed to participate in study (written informed consent); Pediatric plaque psoriasis:
  • Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication
  • Patients with patient or guardian consent to participate in study (written informed consent); Juvenile idiopathic arthritis:
  • Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication
  • Patients with patient or guardian consent to participate in study (written informed consent)

Who cannot take part

  • Patients who are contraindicated according to national prescribing information
  • Patients participating in other interventional clinical trials

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 100 years old?

Where in South Korea

  • Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea

The 3 groups in the trial

  • Secukinumab - HS

    Participants with Hidradenitis Supurativa who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

    Treatment: Secukinumab

  • Secukinumab - Pediatric plaque psoriasis

    Participants with pediatric plaque psoriasis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

    Treatment: Secukinumab

  • Secukinumab - JIA

    Participants with juvenile idiopathic arthritis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

    Treatment: Secukinumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study
Plain-language title
Safety and effectiveness of secukinumab in skin and joint conditions in KoreaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07243782, who can take part
Record updated
5 March 2026